Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

被引:75
作者
Ashrafizadeh, Milad [1 ,2 ]
Zarrabi, Ali [2 ]
Hushmandi, Kiavash [3 ]
Hashemi, Farid [4 ]
Moghadam, Ebrahim Rahmani [5 ]
Raei, Mehdi [6 ]
Kalantari, Mahshad [7 ]
Tavakol, Shima [8 ]
Mohammadinejad, Reza [9 ]
Najafi, Masoud [11 ,12 ]
Tay, Franklin R. [10 ]
Makvandi, Pooyan [13 ,14 ]
机构
[1] Sabanci Univ, Fac Engn & Nat Sci, TR-34956 Istanbul, Turkey
[2] Sabanci Univ Nanotechnol Res & Applicat Ctr SUNUM, TR-34956 Istanbul, Turkey
[3] Univ Tehran, Fac Vet Med, Dept Food Hyg & Qual Control, Div Epidemiol & Zoonoses, Tehran 1419963114, Iran
[4] Univ Tehran, Fac Vet Med, Dept Comparat Biosci, Tehran, Iran
[5] Shiraz Univ Med Sci, Sch Med, Dept Anat Sci, Student Res Comm, Shiraz 7134814336, Iran
[6] Baqiyatallah Univ Med Sci, Hlth Res Ctr, Life Style Inst, Tehran 1435916471, Iran
[7] Azad Univ, Dept Genet, Tehran Med Sci Branch, Tehran 19168931813, Iran
[8] Iran Univ Med Sci, Cellular & Mol Res Ctr, Tehran 1449614525, Iran
[9] Kerman Univ Med Sci, Pharmaceut Res Ctr, Inst Neuropharmacol, Kerman 7616911319, Iran
[10] Augusta Univ, Coll Grad Studies, Augusta, GA 30912 USA
[11] Kermanshah Univ Med Sci, Med Technol Res Ctr, Inst Hlth Technol, Sch Paramed Sci, Kermanshah 6715847141, Iran
[12] Kermanshah Univ Med Sci, Sch Paramed Sci, Radiol & Nucl Med Dept, Kermanshah 6715847141, Iran
[13] Ist Italiano Tecnol, Ctr MicroBioRobot, I-56025 Pisa, Italy
[14] Iran Univ Med Sci, Fac Adv Technol Med, Dept Med Nanotechnol, Tehran 1449614535, Iran
基金
英国科研创新办公室;
关键词
anticancer therapy; chemotherapy; co-delivery platforms; nanocarriers; natural products; small interfering RNA; LOW-DENSITY-LIPOPROTEIN; MESOPOROUS SILICA NANOPARTICLES; CHITOSAN-BASED NANOPARTICLES; EPITHELIAL-MESENCHYMAL TRANSITION; ENHANCED ANTICANCER EFFICACY; MODIFIED CATIONIC LIPOSOMES; SOLID LIPID NANOPARTICLES; CELL-CYCLE REDISTRIBUTION; ANTI-SURVIVIN SIRNA; NANO-GRAPHENE OXIDE;
D O I
10.1021/acscombsci.0c00099
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, codelivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.
引用
收藏
页码:669 / 700
页数:32
相关论文
共 411 条
[51]   Delivery of siRNA to Ewing Sarcoma Tumor Xenografted on Mice, Using Hydrogenated Detonation Nanodiamonds: Treatment Efficacy and Tissue Distribution [J].
Claveau, Sandra ;
Nehlig, Emilie ;
Garcia-Argote, Sebastien ;
Feuillastre, Sophie ;
Pieters, Gregory ;
Girard, Hugues A. ;
Arnault, Jean-Charles ;
Treussart, Francois ;
Bertrand, Jean-Remi .
NANOMATERIALS, 2020, 10 (03)
[52]   Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous nonesmall-cell lung cancer: Results of the IFCT-1103 ULTIMATE study [J].
Cortot, Alexis B. ;
Audigier-Valette, Clarisse ;
Molinier, Olivier ;
Le Moulec, Sylvestre ;
Barlesi, Fabrice ;
Zalcman, Gerard ;
Dumont, Patrick ;
Pouessel, Damien ;
Poulet, Claire ;
Fontaine-Delaruelle, Clara ;
Hiret, Sandrine ;
Dixmier, Adrien ;
Renault, Patrick-Aldo ;
Becht, Catherine ;
Raffy, Olivier ;
Dayen, Charles ;
Mazieres, Julien ;
Pichon, Eric ;
Langlais, Alexandra ;
Morin, Franck ;
Moro-Sibilot, Denis ;
Besse, Benjamin .
EUROPEAN JOURNAL OF CANCER, 2020, 131 :27-36
[53]   Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells [J].
Cristofolini, Tatiane ;
Dalmina, Milene ;
Sierra, Jelver A. ;
Silva, Adny H. ;
Pasa, Andre A. ;
Pittella, Frederico ;
Creczynski-Pasa, Tania B. .
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2020, 109 (109)
[54]   Modeling RNA interference in mammalian cells [J].
Cuccato, Giulia ;
Polynikis, Athanasios ;
Siciliano, Velia ;
Graziano, Mafalda ;
di Bernardo, Mario ;
di Bernardo, Diego .
BMC SYSTEMS BIOLOGY, 2011, 5
[55]   Exosomal miR-200c suppresses chemoresistance of docetaxel in tongue squamous cell carcinoma by suppressing TUBB3 and PPP2R1B [J].
Cui, Jun ;
Wang, Haiyan ;
Zhang, Xiaohe ;
Sun, Xiaodong ;
Zhang, Jin ;
Ma, Jinji .
AGING-US, 2020, 12 (08) :6756-6773
[56]   Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment [J].
Cummings, James C. ;
Zhang, Haiwen ;
Jakymiw, Andrew .
TRANSLATIONAL RESEARCH, 2019, 214 :92-104
[57]   Current perspectives on camptothecins in cancer treatment [J].
Dancey, J ;
Eisenhauer, EA .
BRITISH JOURNAL OF CANCER, 1996, 74 (03) :327-338
[58]   Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia [J].
de Almeida, Patricia E. ;
Mak, Judy ;
Hernandez, Genevive ;
Jesudason, Rajiv ;
Herault, Aurelie ;
Javinal, Vincent ;
Borneo, Jovencio ;
Kim, Jeong M. ;
Walsh, Kevin B. .
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (06) :806-818
[59]  
De Boer JP, 2012, ONCOTARGET, V3, P1169
[60]   Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? [J].
de Erauso, Luisa Chocarro ;
Zuazo, Miren ;
Arasanz, Hugo ;
Bocanegra, Ana ;
Hernandez, Carlos ;
Fernandez, Gonzalo ;
Garcia-Granda, Maria Jesus ;
Blanco, Ester ;
Vera, Ruth ;
Kochan, Grazyna ;
Escors, David .
FRONTIERS IN PHARMACOLOGY, 2020, 11